文献速递肾移植

死亡供肾获取活检的可重复性与预后价值评估

Procurement Biopsies in the Evaluation of Deceased Donor Kidneys.
PubMed 文献 · Clin J Am Soc Nephrol · 2018-10-25

该回顾性单中心连续队列纳入2006至2009年死亡供肾移植,比较获取时冰冻切片活检与再灌注石蜡包埋活检(n=270)及同一肾脏重复获取活检(n=116)的一致性,并分析其与移植物存活的关系。结果显示获取活检可重复性差、与再灌注活检相关性弱,且与移植结局无显著关联,再灌注活检预后价值更优。

要点

  • 获取活检可重复性差,同一肾脏重复活检分类一致率仅64%(κ=0.14)。
  • 获取活检与再灌注活检分类一致率仅64%(κ=0.25),肾小球硬化比例一致率63%(κ=0.15)。
  • 获取活检与移植物失败无显著关联,再灌注活检预后价值更优。

核心结论

  • 获取活检可重复性差,与再灌注石蜡包埋活检相关性弱,且与移植结局无显著关联。

研究设计与样本

  • 回顾性单中心连续队列,纳入2006至2009年死亡供肾移植,比较获取冰冻切片活检与再灌注石蜡包埋活检(n=270),并分析同一肾脏重复获取活检(n=116)的一致性。

主要发现

  • 同一肾脏重复获取活检分类一致率64%(κ=0.14)。
  • 获取与再灌注活检分类一致率64%(κ=0.25),肾小球硬化比例一致率63%(κ=0.15),间质纤维化/肾小管萎缩一致率82%(κ=0.13),血管病变一致率80%(κ=0.15)。
  • 再灌注活检与移植物失败风险比2.02(95%CI 1.09至3.74),获取活检风险比1.30(95%CI 0.61至2.76),获取活检与移植物失败无显著关联。

临床怎么用

  • 获取活检结果解读需谨慎,不宜单独作为弃用供肾的主要依据。
  • 再灌注活检对移植结局的预后判断价值优于获取活检。

局限性

  • 回顾性单中心研究,样本量有限,结论外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Biopsies taken at deceased donor kidney procurement continue to be cited as a leading reason for discard; however, the reproducibility and prognostic capability of these biopsies are controversial. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We compiled a retrospective, single-institution, continuous cohort of deceased donor kidney transplants performed from 2006 to 2009. Procurement biopsy information-percentage of glomerulosclerosis, interstitial fibrosis/tubular atrophy, and vascular disease-was obtained from the national transplant database. Using univariable, multivariable, and time-to-event analyses for death-censored graft survival, we compared procurement frozen section biopsy reports with reperfusion paraffin-embedded biopsies read by trained kidney pathologists (n=270). We also examined agreement for sequential procurement biopsies performed on the same kidney (n=116 kidneys). RESULTS: For kidneys on which more than one procurement biopsy was performed (n=116), category agreement was found in only 64% of cases (κ=0.14). For all kidneys (n=270), correlation between procurement and reperfusion biopsies was poor: overall, biopsies were classified into the same category (optimal versus suboptimal) in only 64% of cases (κ=0.25). This discrepancy was most pronounced when categorizing percentage of glomerulosclerosis, which had 63% agreement (κ=0.15). Interstitial fibrosis/tubular atrophy and vascular disease had agreement rates of 82% (κ=0.13) and 80% (κ=0.15), respectively. Ninety-eight (36%) recipients died, and 56 (21%) allografts failed by the end of follow-up. Reperfusion biopsies were more prognostic than procurement biopsies (hazard ratio for graft failure, 2.02; 95% confidence interval, 1.09 to 3.74 versus hazard ratio for graft failure, 1.30; 95% confidence interval, 0.61 to 2.76), with procurement biopsies not significantly associated with graft failure. CONCLUSIONS: We found that procurement biopsies are poorly reproducible, do not correlate well with paraffin-embedded reperfusion biopsies, and are not significantly associated with transplant outcomes.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Carpenter D, Husain SA, Brennan C, et al. Procurement Biopsies in the Evaluation of Deceased Donor Kidneys. Clin J Am Soc Nephrol. 2018. PMID: 30361336. doi:10.2215/CJN.04150418

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。